My research focuses on identifying risk factors and predictors of prostate cancer development and progression. I am currently involved with large-scale studies to identify genes and genetic variants that can distinguish indolent from lethal prostate cancer at diagnosis. I am particularly interested in combining different types of biological data, such as genetics, RNA and protein expression, and metabolomics, to create a more comprehensive picture of the biology of prostate cancer and disease progression. I am working to explore the relationship of known prostate cancer risk variants with genome-wide expression levels from prostate cancer tissue. I am also further exploring results obtained from developing a mRNA molecular signature of Gleason grade using metabolomics data.